Identification of SARS-CoV-2 viral entry inhibitors using machine learning and cell-based pseudotyped particle assay
Hongmao Sun(National Center for Advancing Translational Sciences), Min Shen(Kaili University), Wei Zheng(Liaoning Cancer Hospital & Institute), Yuhong Wang(Wuhan University), Miao Xu(National Center for Advancing Translational Sciences), Catherine Z. Chen(National Institutes of Health), Hui Guo(First Affiliated Hospital of Xi'an Jiaotong University), Misha Itkin(National Institutes of Health)
Cited by 12
Related Papers
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
|Cell|2020|802
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium
|Cell stem cell|2020|460
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2015|348
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs
|Emerging Microbes & Infections|2014|242
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
|ACS Pharmacology & Translational Science|2020|225